Targeting the IRAK1–S100A9 Axis Overcomes Resistance to Paclitaxel in Nasopharyngeal Carcinoma-Reference-Cited by-同舟云学术

Targeting the IRAK1–S100A9 Axis Overcomes Resistance to Paclitaxel in Nasopharyngeal Carcinoma

Published:2021-01-05 Issue:5 Volume:81 Page:1413-1425
ISSN:0008-5472
Container-title:Cancer Research
language:en
Short-container-title:Cancer Res

Author:

Liu Lizhen,Liu Sailan,Deng Peng,Liang Yujing,Xiao Rong,Tang Lin-Quan,Chen Jinghong^ORCID,Chen Qiu-Yan,Guan Peiyong,Yan Shu-Mei,Huang Xiangliang,Hong Jing Han,Chen Jianfeng,Sun Yichen,Teh Bin Tean,Yu Qiang,Mai Hai-Qiang,Tan Jing

Funder

China Postdoctoral Science Foundation

National Natural Science Foundation of China

Guangdong Innovative and Entrepreneurial Research Team Program

The Sci-Tech Project Foundation of Guangzhou city

Bureau of Science and Information Technology of Guangzhou Municipality | Pearl River S and T Nova Program of Guangzhou

the Natural Science Foundation of Guangdong Province for Distinguished Young Scholar

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Elucidating the pan-oncologic landscape of S100A9: prognostic and therapeutic corollaries from an integrative bioinformatics and Mendelian randomization analysis;Scientific Reports;2024-08-17

2. The m6A reader HNRNPC promotes glioma progression by enhancing the stability of IRAK1 mRNA through the MAPK pathway;Cell Death & Disease;2024-06-03

3. Prognostic biomarker discovery based on proteome landscape of Chinese lung adenocarcinoma;Clinical Proteomics;2024-01-05

4. Potential applications of JAK inhibitors, clinically approved drugs against autoimmune diseases, in cancer therapy;Frontiers in Pharmacology;2024-01-03

5. Glioma-derived S100A9 polarizes M2 microglia to inhibit CD8+T lymphocytes for immunosuppression via αvβ3 integrin/AKT1/TGFβ1;Biochimica et Biophysica Acta (BBA) - Molecular Cell Research;2024-01